Muscle GrowthAnti-AgingLongevityWell-evidencedHuman trials

IGF-1

Insulin-like Growth Factor 1

Overview

Insulin-like Growth Factor 1 (IGF-1) is a naturally occurring 70-amino-acid peptide hormone produced primarily in the liver in response to growth hormone stimulation. It is the primary mediator of growth hormone's anabolic and growth-promoting effects throughout the body. IGF-1 plays a fundamental role in childhood growth, adult tissue maintenance, muscle protein synthesis, bone density, and cellular metabolism. Recombinant human IGF-1 (mecasermin) is FDA-approved for IGF-1 deficiency and has been studied extensively in aging, muscle wasting, and metabolic disorders. It is one of the most studied peptides in endocrinology.

Where does IGF-1 sit?

See how this peptide compares across all 70 peptides in our database.

Mechanism of Action

IGF-1 acts by binding to the IGF-1 receptor (IGF-1R), a tyrosine kinase receptor expressed in virtually every tissue. Receptor activation triggers the PI3K/Akt and MAPK/ERK signaling cascades, which regulate cell growth, differentiation, survival, and metabolism. In muscle tissue, IGF-1 activates satellite cells and stimulates protein synthesis through mTOR pathway activation, promoting hypertrophy and repair. In bone, it stimulates osteoblast proliferation and collagen synthesis. IGF-1 also has insulin-like metabolic effects including glucose uptake promotion in peripheral tissues. In the brain it acts as a neurotrophic factor supporting neuronal survival and synaptic plasticity. Its signaling is modulated by a family of IGF-binding proteins (IGFBPs) that regulate bioavailability.

Dosage Information

Typical Dose

20-120 mcg/kg daily (clinical), 50-100 mcg (research protocols)

Frequency

Once or twice daily

Administration

Subcutaneous injection

Notes

Must be administered with food to reduce hypoglycemia risk. Clinical use requires medical supervision. Research use protocols vary widely. Often stacked with GH secretagogues.

Potential Side Effects

Hypoglycemia — most significant risk, administer with food (common at higher doses)Jaw pain or facial bone changes with long-term high-dose use (uncommon)Edema (uncommon)Headache (uncommon)Potential mitogenic effects — theoretical cancer promotion concern with long-term use

Community Experiences

Share Your Experience

Sign in to track your experience history and vote on others.
Verifying...

No experiences shared yet. Be the first!

Quick Facts

Administration
Subcutaneous injection
Typical Dose
20-120 mcg/kg daily (clinical), 50-100 mcg (research protocols)
Frequency
Once or twice daily
References
0 curated + 49 from PubMed
Clinical Trials
49 registered
Evidence Score
78.0 / 100